share_log

bluebird bio | PRE 14A: Preliminary proxy statements relating to merger or acquisition

bluebird bio | PRE 14A: Preliminary proxy statements relating to merger or acquisition

bluebird bio | PRE 14A:並購重組委托聲明
美股SEC公告 ·  09/16 16:08

Moomoo AI 已提取核心訊息

bluebird bio, Inc. (bluebird) has announced the filing of a preliminary proxy statement with the U.S. Securities and Exchange Commission (SEC) for its 2024 Annual Meeting of Stockholders. The proxy statement includes proposals for stockholder consideration, such as the election of three Class II directors, advisory votes on executive compensation, and amendments to the company's Certificate of Incorporation for a reverse stock split and officer exculpation provisions. The meeting is scheduled for November 6, 2024, at the company's offices in Somerville, Massachusetts. Stockholders are encouraged to vote their shares prior to the meeting. The proxy materials will be available to stockholders via the Internet at www.proxyvote.com, with instructions for accessing the materials and voting described in the Notice of Internet Availability of Proxy Materials mailed to stockholders. The board has recommended voting in favor of all proposals, including the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
bluebird bio, Inc. (bluebird) has announced the filing of a preliminary proxy statement with the U.S. Securities and Exchange Commission (SEC) for its 2024 Annual Meeting of Stockholders. The proxy statement includes proposals for stockholder consideration, such as the election of three Class II directors, advisory votes on executive compensation, and amendments to the company's Certificate of Incorporation for a reverse stock split and officer exculpation provisions. The meeting is scheduled for November 6, 2024, at the company's offices in Somerville, Massachusetts. Stockholders are encouraged to vote their shares prior to the meeting. The proxy materials will be available to stockholders via the Internet at www.proxyvote.com, with instructions for accessing the materials and voting described in the Notice of Internet Availability of Proxy Materials mailed to stockholders. The board has recommended voting in favor of all proposals, including the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
bluebird bio, Inc.(藍鳥生物)已向美國證券交易委員會(SEC)提交了一份初步代理人聲明,用於2024年股東年會。代理人聲明包括股東考慮的提案,如選舉三名二級董事、對高管薪酬進行諮詢審議,並對公司章程進行修訂,包括逆向股份拆分和高級幹部免責規定。會議定於2024年11月6日在馬薩諸塞州薩默維爾的公司辦公室舉行。鼓勵股東在會議前投票表決。代理人材料將通過互聯網提供給股東,股東會收到《代理人材料互聯網可得通知》,其中描述了獲取材料和投票的說明。董事會建議投票支持所有提案,包括批准安永(Ernst & Young LLP)爲2024年12月31日結束的財年獨立註冊會計師事務所。
bluebird bio, Inc.(藍鳥生物)已向美國證券交易委員會(SEC)提交了一份初步代理人聲明,用於2024年股東年會。代理人聲明包括股東考慮的提案,如選舉三名二級董事、對高管薪酬進行諮詢審議,並對公司章程進行修訂,包括逆向股份拆分和高級幹部免責規定。會議定於2024年11月6日在馬薩諸塞州薩默維爾的公司辦公室舉行。鼓勵股東在會議前投票表決。代理人材料將通過互聯網提供給股東,股東會收到《代理人材料互聯網可得通知》,其中描述了獲取材料和投票的說明。董事會建議投票支持所有提案,包括批准安永(Ernst & Young LLP)爲2024年12月31日結束的財年獨立註冊會計師事務所。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息